ID=wsj_0180.1 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 0 2> (<T NP 0 2> (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP Genetics N_85/N_85>) (<T N 1 2> (<L N/N NNP NNP Institute N_78/N_78>) (<L N NNP NNP Inc. N>) ) ) ) (<L , , , , ,>) ) (<T NP\NP 1 2> (<L (NP\NP)/(NP\NP) NNP NNP Cambridge (NP_111\NP_105)_111/(NP_111\NP_105)_111>) (<T NP\NP 1 2> (<L , , , , ,>) (<L NP\NP NNP NNP Mass. NP_95\NP_95>) ) ) ) (<L , , , , ,>) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[dcl] VBD VBD said (S[dcl]\NP_8)/S[dcl]_9>) (<T S[dcl] 1 2> (<L NP PRP PRP it NP>) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[pss]\NP) VBD VBD was (S[dcl]\NP_18)/(S[pss]_19\NP_18:B)_19>) (<T S[pss]\NP 0 2> (<T (S[pss]\NP)/PP 0 2> (<L ((S[pss]\NP)/PP)/NP VBN VBN awarded ((S[pss]\NP_28)/PP_29)/NP_30>) (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP U.S. N_39/N_39>) (<L N NNS NNS patents N>) ) ) ) (<T PP 0 2> (<L PP/NP IN IN for PP/NP_45>) (<T NP 0 2> (<T NP 0 1> (<L N NN NN Interleukin-3 N>) ) (<T NP[conj] 1 2> (<L conj CC CC and conj>) (<T NP 0 1> (<T N 1 2> (<L N/N NN NN bone N_64/N_64>) (<T N 1 2> (<L N/N JJ JJ morphogenetic N_57/N_57>) (<L N NN NN protein N>) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_0180.2 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT The NP[nb]_212/N_212>) (<L N NN NN patent N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN for (NP_220\NP_220)/NP_221>) (<T NP 0 1> (<L N NN NN Interleukin-3 N>) ) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/NP VBZ VBZ covers (S[dcl]\NP_98)/NP_99>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N NNS NNS materials N>) (<T N[conj] 1 2> (<L conj CC CC and conj>) (<L N NNS NNS methods N>) ) ) ) (<T NP\NP 0 1> (<T S[pss]\NP 0 2> (<L (S[pss]\NP)/(S[to]\NP) VBN VBN used (S[pss]\NP_115)/(S[to]_116\NP_115:B)_116>) (<T S[to]\NP 0 2> (<L (S[to]\NP)/(S[b]\NP) TO TO to (S[to]\NP_125)/(S[b]_126\NP_125:B)_126>) (<T S[b]\NP 0 2> (<T S[b]\NP 0 2> (<L (S[b]\NP)/NP VB VB make (S[b]\NP_133)/NP_134>) (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_169/N_169>) (<T N 1 2> (<L N/N JJ JJ human N_164/N_164>) (<T N 1 2> (<L N/N NN NN blood N_157/N_157>) (<T N 1 2> (<L N/N NN NN cell N_150/N_150>) (<T N 1 2> (<L N/N NN NN growth N_143/N_143>) (<L N NN NN factor N>) ) ) ) ) ) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN via ((S_182\NP_177)_182\(S_182\NP_177)_182)/NP_183>) (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ recombinant N_199/N_199>) (<T N 1 2> (<L N/N NNP NNP DNA N_192/N_192>) (<L N NN NN technology N>) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_0180.3 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP Sandoz N_241/N_241>) (<L N NNP NNP Ltd. N>) ) ) (<T S[dcl]\NP 0 2> (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[pt]\NP) VBZ VBZ has (S[dcl]\NP_121)/(S[pt]_122\NP_121:B)_122>) (<T S[pt]\NP 0 2> (<T (S[pt]\NP)/PP 0 2> (<L ((S[pt]\NP)/PP)/NP VBN VBN licensed ((S[pt]\NP_131)/PP_132)/NP_133>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ certain N_158/N_158>) (<T N 1 2> (<L N/N NN NN manufacturing N_151/N_151>) (<T N 1 2> (<L conj CC CC and conj>) (<T N 1 2> (<L N/N NN NN marketing N_142/N_142>) (<L N NNS NNS rights N>) ) ) ) ) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN for (NP_167\NP_167)/NP_168>) (<T NP 0 1> (<L N NN NN Interleukin-3 N>) ) ) ) ) (<T PP 0 2> (<L PP/NP IN IN from PP/NP_176>) (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP Genetics N_185/N_185>) (<L N NNP NNP Institute N>) ) ) ) ) ) (<T S[dcl]\NP[conj] 1 2> (<L conj CC CC and conj>) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[ng]\NP) VBZ VBZ is (S[dcl]\NP_195)/(S[ng]_196\NP_195:B)_196>) (<T S[ng]\NP 0 2> (<T S[ng]\NP 0 2> (<L (S[ng]\NP)/NP VBG VBG conducting (S[ng]\NP_203)/NP_204>) (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ preclinical N_213/N_213>) (<L N NNS NNS studies N>) ) ) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN with ((S_227\NP_222)_227\(S_227\NP_222)_227)/NP_228>) (<L NP PRP PRP it NP>) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_0180.4 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T S[dcl] 1 2> (<T NP 0 1> (<L N NN NN Interleukin-3 N>) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[b]\NP) MD MD may (S[dcl]\NP_139)/(S[b]_140\NP_139:B)_140>) (<T S[b]\NP 0 2> (<L S[b]\NP VB VB help S[b]\NP_145>) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/(S[ng]\NP) IN IN in ((S_160\NP_153)_160\(S_160\NP_153)_160)/(S[ng]_161\NP_153:B)_161>) (<T S[ng]\NP 0 2> (<L (S[ng]\NP)/NP VBG VBG treating (S[ng]\NP_168)/NP_169>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NN NN blood N_185/N_185>) (<T N 1 2> (<L N/N NN NN cell N_178/N_178>) (<L N NNS NNS deficiencies N>) ) ) ) (<T NP\NP 0 1> (<T S[pss]\NP 0 2> (<L (S[pss]\NP)/PP VBN VBN associated (S[pss]\NP_193)/PP_194>) (<T PP 0 2> (<L PP/NP IN IN with PP/NP_199>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NN NN cancer N_208/N_208>) (<L N NN NN treatment N>) ) ) (<T NP[conj] 1 2> (<L , , , , ,>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NN NN bone N_225/N_225>) (<T N 1 2> (<L N/N NN NN marrow N_218/N_218>) (<L N NNS NNS transplants N>) ) ) ) (<T NP[conj] 1 2> (<L conj CC CC and conj>) (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ other N_242/N_242>) (<T N 1 2> (<L N/N NN NN blood-cell N_235/N_235>) (<L N NNS NNS disorders N>) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) (<T S[dcl]\S[dcl] 1 2> (<L , , , , ,>) (<T S[dcl]\S[dcl] 1 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP Genetics N_127/N_127>) (<L N NNP NNP Institute N>) ) ) (<L (S[dcl]\S[dcl])\NP VBD VBD said (S[dcl]\S[dcl]_117)\NP_118>) ) ) ) (<L . . . . .>) ) 
ID=wsj_0180.5 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT The NP[nb]_216/N_216>) (<T N 1 2> (<L N/N JJ JJ second N_211/N_211>) (<L N NN NN patent N>) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/NP VBZ VBZ describes (S[dcl]\NP_124)/NP_125>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NN NN bone N_141/N_141>) (<T N 1 2> (<L N/N JJ JJ morphogenetic N_134/N_134>) (<L N NN NN protein-1 N>) ) ) ) (<T NP[conj] 1 2> (<L , , , , ,>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT a NP[nb]_149/N_149>) (<L N NN NN substance N>) ) (<T NP\NP 0 2> (<L (NP\NP)/(S[dcl]\NP) WDT WDT that (NP_159\NP_159)/(S[dcl]_160\NP_159:B)_160>) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[b]\NP) MD MD can (S[dcl]\NP_169)/(S[b]_170\NP_169:B)_170>) (<T S[b]\NP 0 2> (<L (S[b]\NP)/NP VB VB induce (S[b]\NP_177)/NP_178>) (<T NP 0 2> (<T NP 0 1> (<L N NN NN formation N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_189\NP_189)/NP_190>) (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ new N_199/N_199>) (<L N NN NN cartilage N>) ) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_0180.6 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT The NP[nb]_191/N_191>) (<L N NN NN patent N>) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/NP VBZ VBZ covers (S[dcl]\NP_112)/NP_113>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NN NN BMP-1 N_129/N_129>) (<T N 1 2> (<L N/N NN NN type N_122/N_122>) (<L N NNS NNS proteins N>) ) ) ) (<T NP[conj] 1 2> (<L conj CC CC and conj>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ pharmaceutical N_143/N_143>) (<T N 1 2> (<L N NNS NNS compositions N>) (<T N[conj] 1 2> (<L conj CC CC and conj>) (<L N NNS NNS methods N>) ) ) ) ) (<T NP\NP 0 2> (<L (NP\NP)/(S[ng]\NP) IN IN for (NP_154\NP_154)/(S[ng]_155\NP_151)_155>) (<T S[ng]\NP 0 2> (<L (S[ng]\NP)/NP VBG VBG treating (S[ng]\NP_162)/NP_163>) (<T NP 0 1> (<T N 1 2> (<L N/N NN NN bone N_181/N_181>) (<T N 1 2> (<L conj CC CC or conj>) (<T N 1 2> (<L N/N NN NN cartilage N_172/N_172>) (<L N NNS NNS defects N>) ) ) ) ) ) ) ) ) ) ) ) (<T S[dcl]\S[dcl] 1 2> (<L , , , , ,>) (<T S[dcl]\S[dcl] 1 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP Genetics N_102/N_102>) (<L N NNP NNP Institute N>) ) ) (<L (S[dcl]\S[dcl])\NP VBD VBD said (S[dcl]\S[dcl]_92)\NP_93>) ) ) ) (<L . . . . .>) ) 
ID=wsj_0180.7 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT The NP[nb]_181/N_181>) (<L N NN NN company N>) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[em] VBD VBD added (S[dcl]\NP_90)/S[em]_91>) (<T S[em] 0 2> (<L S[em]/S[dcl] IN IN that S[em]/S[dcl]_96>) (<T S[dcl] 1 2> (<L NP PRP PRP it NP>) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[pt]\NP) VBZ VBZ has (S[dcl]\NP_105)/(S[pt]_106\NP_105:B)_106>) (<T S[pt]\NP 0 2> (<T (S[pt]\NP)/PP 0 2> (<L ((S[pt]\NP)/PP)/NP VBN VBN filed ((S[pt]\NP_115)/PP_116)/NP_117>) (<T NP 0 1> (<T N 1 2> (<L N/N NN NN patent N_126/N_126>) (<L N NNS NNS applications N>) ) ) ) (<T PP 0 2> (<L PP/NP IN IN on PP/NP_132>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT a NP[nb]_146/N_146>) (<T N 1 2> (<L N/N JJ JJ large N_141/N_141>) (<L N NN NN number N>) ) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_154\NP_154)/NP_155>) (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ different N_171/N_171>) (<T N 1 2> (<L N/N NN NN BMP N_164/N_164>) (<L N NNS NNS proteins N>) ) ) ) ) ) ) ) ) ) ) ) ) (<T S[dcl][conj] 1 2> (<L conj CC CC and conj>) (<T S[dcl] 1 2> (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_235/N_235>) (<L N NN NN patent N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN on (NP_243\NP_243)/NP_244>) (<T NP 0 1> (<L N NN NN BMP-1 N>) ) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/NP VBZ VBZ is (S[dcl]\NP_188)/NP_189>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_196/N_196>) (<L N NN JJ first N>) ) (<T NP\NP 0 1> (<T S[dcl]/NP 1 2> (<T S/(S\NP) 0 1> (<L NP PRP PRP it NP>) ) (<T (S[dcl]\NP)/NP 0 2> (<L (S[dcl]\NP)/(S[pt]\NP) VBZ VBZ has (S[dcl]\NP_205)/(S[pt]_206\NP_205:B)_206>) (<L (S[pt]\NP)/NP VBN VBN received (S[pt]\NP_213)/NP_214>) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_0180.8 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T S[dcl] 1 2> (<T NP 0 1> (<T N 1 2> (<L N/N NN NN BMP N_283/N_283>) (<L N NNS NNS products N>) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[b]\NP) MD MD may (S[dcl]\NP_158)/(S[b]_159\NP_158:B)_159>) (<T S[b]\NP 0 2> (<T S[b]\NP 0 2> (<L (S[b]\NP)/(S[adj]\NP) VB VB be (S[b]\NP_168)/(S[adj]_169\NP_168:B)_169>) (<L S[adj]\NP JJ JJ useful S[adj]\NP_174>) ) (<T (S\NP)\(S\NP) 0 2> (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN in ((S_187\NP_182)_187\(S_187\NP_182)_187)/NP_188>) (<T NP 0 1> (<T N 1 2> (<L N/N NN NN fracture N_197/N_197>) (<L N NN NN healing N>) ) ) ) (<T (S\NP)\(S\NP)[conj] 1 2> (<L conj CC CC and conj>) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/(S[ng]\NP) IN IN in ((S_213\NP_206)_213\(S_213\NP_206)_213)/(S[ng]_214\NP_206:B)_214>) (<T S[ng]\NP 0 2> (<L (S[ng]\NP)/NP VBG VBG treating (S[ng]\NP_221)/NP_222>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NN NN bone N_231/N_231>) (<L N NN NN loss N>) ) ) (<T NP\NP 0 1> (<T S[pss]\NP 0 2> (<L (S[pss]\NP)/PP VBN VBN associated (S[pss]\NP_239)/PP_240>) (<T PP 0 2> (<L PP/NP IN IN with PP/NP_245>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ periodontal N_254/N_254>) (<L N NN NN disease N>) ) ) (<T NP[conj] 1 2> (<L conj CC CC and conj>) (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ certain N_264/N_264>) (<L N NNS NNS cancers N>) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) (<T S[dcl]\S[dcl] 1 2> (<L , , , , ,>) (<T S[dcl]\S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_147/N_147>) (<L N NN NN company N>) ) (<L (S[dcl]\S[dcl])\NP VBD VBD said (S[dcl]\S[dcl]_139)\NP_140>) ) ) ) (<L . . . . .>) ) 
